Sudeep Pharma IPO Share Price Highlights: Stock ends 30% over issue price in stellar market debut

Sudeep Pharma share price ended at ₹773.70 apiece on the BSE, a premium of 30.47% over its IPO price and 5.42% over its listing price. Meanwhile, on the NSE, the stock ended at ₹771.85, up 30.16% over IPO price and 5.73% above listing price.

Despite weakness in the Indian stock market, Sudeep Pharma share price traded in the green. The stock rose to ₹795.80, a premium of 34% over the IPO price. At 2.30 am, when the Indian stock market's benchmark Sensex was trading in the red, Sudeep Pharma share price was at ₹793, up 8% over listing price and 33.7% over IPO price.

Sudeep Pharma's market cap has risen to over ₹8800 crore following the stellar debut on the Indian stock market.

For FY23, the company's profit stood at ₹62.32 crore, which rose to ₹133.19 crore in FY24 and to ₹138.69 crore in FY25. For the first three months in FY26, the company's profit was ₹30.81 crore. The company's revenue from operations in FY23 was ₹428.74 crore, while in FY24 and in FY25 it was ₹459.28 crore and ₹502 crore, respectively. For the three-month period ended 30 June 2025, its revenue was ₹124.92 crore.

Sudeep Pharma’s debuted the market today with encouraging 23% premium to its issue price, clearly reflecting strong investor confidence across categories. The high participation was primarily driven by solid institutional participation which underlines trust in company’s focused presence in pharmaceutical excipients and specialty ingredients. A space which is characterised by high entry barriers, stringent regulatory requirements and steadily rising global demand from the pharma, nutraceutical and food segments.

Over the years, Sudeep Pharma has established itself as a strong supplier with a diversified export base and placing it in a favourable position to benefit from India’s expanding footprint in the global pharmaceutical value chain.

While near-term challenges such as pricing pressures and trade uncertainties may weigh on the sentiment in the broader Indian pharma space, the longer-term outlook remains positive, supported by heightened focus on healthcare and sustained demand for high-grade ingredients.

From an investor’s perspective, Sudeep Pharma presents a compelling long-term story with opportunities in scalability and industry tailwinds, though seeing valuations post-listing, a sustained earnings growth and margin discipline will be crucial in justifying further upside.

— Dr. Ravi Singh, Chief Research Officer from Master Capital Services

Sudeep Pharma on Thursday said it has mobilised ₹268.5 crore from anchor investors ahead of its initial public offering (IPO).

Some of the institutions that participated in the anchor include SBI Mutual Fund (MF), HDFC MF, ICICI Prudential MF, Nippon India MF, WhiteOak Capital MF, Aditya Birla Sun Life MF, Motilal Oswal MF, Quant MF, Bandhan MF, UTI MF, Edelweiss MF, Tata AIA Life Insurance and SBI Life Insurance, according to a circular uploaded on BSE's website.

As per the circular, the Vadodara-based company allocated 45,27,823 equity shares at ₹593 per share to anchor investors, raising ₹268.5 crore.

The initial public offering (IPO) was a combination of fresh issue of equity shares worth ₹95 crore and an offer-for-sale of nearly 1.35 crore equity shares, aggregating to ₹800 crore, by the promoters.

Proceeds from the fresh issue to the tune of ₹75.81 crore will be used for capital expenditure toward the procurement of machinery for its production line located at the Nandesari Facility 1, Gujarat, and for general corporate purposes.

Sudeep Pharma delivered an impressive listing on the stock exchanges, opening at ₹733.95 on the BSE and ₹730 on the NSE, marking a 24% premium over its IPO price of ₹593 per share. The strong debut reflects robust investor confidence in the company’s position as a leading player in specialty pharma ingredients and excipients.

The enthusiasm around the IPO was evident well before listing day. In the unlisted market, Sudeep Pharma’s shares were commanding a 20.40% premium, signalling strong demand from early investors. The company’s ₹895 crore IPO saw overwhelming participation, being subscribed 93.72 times, with total bids crossing ₹58,700 crore across 29.86 lakh applications.

Sudeep Pharma’s listing strength is backed by its established presence in pharma and nutraceutical input materials, diversified product portfolio, long-term relationships with leading global pharma companies, and strong export potential. However, in the near term, investors may remain watchful of margin sustainability, raw material price swings, and competitive intensity in specialty chemicals and pharma ingredients.

Given the strong listing pop, investors allocated shares may consider booking partial gains, while aggressive long-term investors bullish on the specialty pharma ingredient space may hold the remaining portion — with a disciplined stop-loss at ₹690.

— Views by Shivani Nyati, Head of Wealth at Swastika Investmart Ltd.

Sudeep Pharma shares extended their gains after a solid listing. The stock rose to ₹777 on the BSE, a premium of 30% over issue price and a gain of nearly 5% over listing price. On NSE, too, the stock rally strengthened, rising to ₹777.25 apiece.

Sudeep Pharma share price lists at 23.77% premium over IPO price at ₹733.95 on the BSE. Meanwhile, on the NSE, Sudeep Pharma stock opened at ₹730, a premium of ₹730.

Sudeep Pharma shares were trading with 23% premium on the NSE in pre-open trade, signaling a listing price of ₹730 as against the IPO price of ₹593.

Sudeep Pharma IPO was subscribed 93.72 times in total, NSE data showed. The public issue was booked 15.65 times in the Retail Individual Investors (RIIs) category, and 116.72 times in the Non Institutional Investors (NII) segment. The Qualified Institutional Buyers (QIBs) category received a massive 213.08 times subscription.

“Trading Members of the Exchange are hereby informed that effective from Friday, November 28, 2025, the equity shares of Sudeep Pharma Limited shall be listed and admitted to dealings on the Exchange in the list of ‘B’ Group of Securities,” said a notice on the BSE.

Ahead of listing Sudeep Pharma IPO GMP is ₹121. With the price band of 593, Sudeep Pharma IPO's estimated listing price is ₹714 (cap price + today's GMP), signalling a listing gains of 20.40%.